Highlights XLIE SCIE OTC Markets

Equities

XLSCF

CH0461929603

Delayed OTC Markets Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	-.--%

Apr. 23	Xlife Sciences Posts Higher FY23 Profit; Revenue Falls	MT
Feb. 29	Xlife Sciences AG Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Xlife Sciences Posts Higher FY23 Profit; Revenue Falls	Apr. 23	MT
Xlife Sciences AG Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Switzerland’s Xlife Sciences, Abu Dhabi Expand Existing Life Sciences Partnership	Feb. 05	MT
Xlife Sciences, Quant Team Up to Develop Biomarkers for Kidney Diseases Detection	Dec. 20	MT
Xlife Sciences to Sell Portfolio Company to 4D Lifetec	23-10-18	MT
Xlife Sciences AG acquired 20% stake in 4D Lifetec AG for CHF 23.3 million.	23-10-17	CI
Xlife Sciences Loss Narrows in H1; Revenue Declines	23-09-21	MT
Xlife Sciences AG Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-20	CI
Xlife Sciences AG Signs Memorandum of Understanding with the Regulator of the Healthcare Sector in the UAE, the Department of Health - Abu Dhabi	23-08-17	CI
Xlife Sciences Posts Lower FY22 EPS; Revenue Increases	23-04-20	MT
Xlife Sciences AG Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-19	CI
Xlife Sciences : Praesentation	23-02-16	PU
Xlife Sciences Portfolio Company Receives European Patent for Biological Tissue Generation Method	23-01-20	MT
Xlife Sciences AG Launches Project to Research a Potential Therapy for Amyotrophic Lateral Sclerosis	23-01-15	CI
Xlife Sciences Portfolio Company Signs Exclusive License Agreement	22-12-01	MT
Xlife Sciences Unit Taps CureDiab For Morbid Obesity Research	22-11-28	MT
Alytas therapeutics collaborates with spin-off from the German Diabetes Center	22-11-28	EQ
Xlife Sciences' Portfolio Company Wins US Patent for Active Ingredient of Inflammatory Pain Drug	22-11-01	MT
Xlife Sciences AG Reports Earnings Results for the Half Year Ended June 30, 2022	22-09-28	CI
Xlife Sciences' H1 Loss Widen, Revenue Jumps in First Report Since SIX Swiss Transfer	22-09-28	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights XLIE SCIE OTC Markets

Equities

XLSCF

CH0461929603

Highlights

Filters